Olmesartan, Amlodipina E Idroclorotiazide Eg (Olmesartan Medoxomil, Hydrochlorothiazide, Amlodipine Besilate)

Olmesartan medoxil blocks the angiotensin II type‑1 receptor, preventing vasoconstriction and aldosterone release; amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation; hydrochlorothiazide reduces sodium and water reabsorption in the distal tubule, lowering plasma volume. The combined actions produce additive blood‑pressure reduction.

The specific dose of Olmesartan, Amlodipina E Idroclorotiazide Eg is determined by the prescribing clinician based on the patient’s blood‑pressure level, renal function and concomitant therapies. The product is supplied as a tablet with a fixed strength, and the prescriber selects the appropriate regimen for each individual.

This combination is contraindicated during pregnancy because olmesartan can cause fetal toxicity and malformations. Use during lactation is not recommended, as the active substances may be excreted in breast milk and could affect the infant. Alternative antihypertensives with established safety profiles should be considered.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with monotherapy using an ARB alone, the triple‑combination offers additional blood‑pressure lowering through calcium‑channel blockade and diuresis, often achieving target pressures more rapidly and with fewer tablets. However, the broader pharmacologic profile may increase the risk of side effects such as edema or electrolyte disturbances, which are less common with single‑agent therapy.

The tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged. No refrigeration is required for this oral formulation.

Olmesartan, Amlodipina E Idroclorotiazide Eg is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush, split or chew unless specifically advised. Consistent timing each day helps maintain stable blood‑pressure control.

Serious adverse reactions include angioedema, severe hypotension, acute renal failure, marked electrolyte imbalances (such as hyperkalemia or hyponatremia), and hepatic dysfunction. Patients should be instructed to seek immediate medical attention if they experience swelling of the face or throat, sudden dizziness, reduced urine output, or unexplained fatigue.

The combination is contraindicated in patients with known hypersensitivity to any component, severe renal or hepatic impairment, pregnancy, and those taking other ARBs, ACE inhibitors, or potassium‑sparing diuretics without close monitoring. Individuals with a history of angioedema or significant hypotension should also avoid this product unless a physician determines that benefits outweigh the risks.